The road to licensure of a DNA vaccine

Current Opinion in Investigational Drugs

Volumn 8, Issue 8, 2007, Pages 635-641

  Salonius, Kira ^a   Simard, Nathalie ^a   Harland, Richard ^b   Ulmer, Jeffrey B ^c  

^a HEALTH CANADA   (Canada)

^b Novartis Animal Health   (United States)

^c Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Adjuvant; Delivery system; Fish; Hematopoietic necrosis virus; Safety

Indexed keywords

CHITOSAN; COPOLYMER; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PLASMID VECTOR; POLYETHYLENEIMINE; POLYGLACTIN; RECOMBINANT PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL HEALTH; ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; FISH DISEASE; GENE DELIVERY SYSTEM; GENE GUN; GENETIC TRANSFECTION; HUMAN; IMMUNOSTIMULATION; INFECTIOUS HEMATOPOIETIC NECROSIS; INFECTIOUS HEMATOPOIETIC NECROSIS VIRUS; LICENSING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VETERINARY MEDICINE;

ANIMALS; FISH DISEASES; HUMANS; INFECTIOUS HEMATOPOIETIC NECROSIS VIRUS; LICENSURE; RHABDOVIRIDAE INFECTIONS; VACCINES, DNA;

EID: 34547635033     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Novartis Animal Health Inc: Novel Novartis vaccine to protect Canadian salmon farms from devastating viral disease. Press Release (2005): July 19.
2. United States Department of Agriculture: USDA issues license for West Nile virus DNA vaccine for horses. Press Release (2005): July 18.
3. Merial Ltd: USDA grants conditional approval for first therapeutic vaccine to treat cancer: Merial's new vaccine treats deadly cancer in dogs. Press Release (2007): March 26.
4. Yasutake WT, Amend DF: Some aspects of pathogenesis of infectious hematopoietic necrosis (IHN). J Fish Biol (1972) 4(1):114-122.
5. Mulcahy D, Wood J: A natural epizootic of infectious haematopoietic necrosis in imported Atlantic salmon, Salmo salar L, reared in the enzootic region. J Fish Dis (1986) 9(2):173-175.
6. Saksida SM: Infectious haematopoietic necrosis epidemic (2001 to 2003) in farmed Atlantic salmon Salmo salar in British Columbia. Dis Aquat Organ (2006) 72(3):213-223.
7. Huang C, Chien M-S, Landolt M, Batts W, Winton J: Mapping the neutralizing epitopes on the glycoprotein of infectious haematopoietic necrosis virus, a fish rhabdovirus. J Gen Virol (1996) 77(12):3033- 3040.
8. Lorenzen N, Olesen NJ, Jorgensen PE: Neutralization of Egtved virus pathogenicity to cell cultures and fish by monoclonal antibodies to the viral G protein. J Gen Virol (1990) 71(3):561-567.
9. Corbeil S, LaPatra SE, Anderson ED, Jones J, Vincent B, Hsu YL, Kurath G: Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of infectious hematopoietic necrosis virus in rainbow trout Oncorhynchus mykiss using DNA vaccines. Dis Aquat Organ (1999) 39(1):29-36.
10. Anderson ED, Mourich DV, Fahrenkrug SC, LaPatra S, Shepherd J, Leong JA: Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol (1996) 5(2):114-122.
11. Saksida SM: Infectious haematopoietic necrosis epidemic (2001 to 2003) in farmed Atlantic salmon Salmo salar in British Columbia. Dis Aquat Organ (2006) 72(3):225-239.
12. Kurath G, Garver KA, Corbeil S, Elliott DG, Anderson ED, LaPatra SE: Protective immunity and lack of histopathological damage two years after DNA vaccination against infectious hematopoietic necrosis virus in trout. Vaccine (2006) 24(3):345-354. • This study demonstrated long-term safety and efficacy of an IHNV DNA vaccine, despite the absence of detectable neutralizing antibodies at the time of challenge. These results are similar to those of a large-scale field trial conducted in support of the licensure of Apex-IHN.
13. Dijkstra JM, Okamoto H, Ototake M, Nakanishi T: Luciferase expression 2 years after DNA injection in glass catfish (Kryptopterus bicirrhus). Fish Shellfish Immunol (2001) 11(2):199-202.
14. Kurath G: Overview of recent DNA vaccine development for fish. Dev Biol (2005) 121:201-213.
15. Acosta F, Collet B, Lorenzen N, Ellis AE: Expression of the glycoprotein of viral haemorrhagic septicaemia virus (VHSV) on the surface of the fish cell line RTG-P1 induces type 1 interferon expression in neighbouring cells. Fish Shellfish Immunol (2006) 21(3):272-278. • One of three papers describing the inherent ability of the rhabdovirus G protein to stimulate the innate immune system of fish, suggesting a role in antiviral immunity.
16. Yasuike M, Kondo H, Hirono I, Aoki T: Difference in Japanese flounder, Paralichthys olivaceus gene expression profile following hirame rhabdovirus (HIRRV) G and N protein DNA vaccination. Fish Shellfish Immunol (2006): doi:10.1016/j.fsi.2006.12.006. • One of three papers describing the inherent ability of the rhabdovirus G protein to stimulate the innate immune system of fish, suggesting a role in antiviral immunity.
17. Purcell MK, Nichols KM, Winton JR, Kurath G, Thorgaard GH, Wheeler P, Hansen JD, Herwig RP, Park LK: Comprehensive gene expression profiling following DNA vaccination of rainbow trout against infectious hematopoietic necrosis virus. Mol Immunol (2006) 43(13):2089-2106. • One of three papers describing the inherent ability of the rhabdovirus G protein to stimulate the innate immune system of fish, suggesting a role in antiviral immunity.
18. Franch R, Cardazzo B, Antonello J, Castagnaro M, Patarnello T, Bargelloni L: Full-length sequence and expression analysis of toll-like receptor 9 in the gilthead seabream (Sparus aurata L.). Gene (2006) 378:42-51. • Demonstration that TLR9 is expressed in fish, suggesting the potential involvement of the fish innate immune system in DNA-vaccine efficacy in this species.
19. Takano T, Kondo H, Hirono I, Endo M, Saito-Taki T, Aoki T: Molecular cloning and characterization of toll-like receptor 9 in Japanese flounder, Paralichthys olivaceus. Mol Immunol (2007) 44(8):1845- 1853. • Demonstration that TLR9 is expressed and functional in fish, suggesting the potential involvement of the fish innate immune system in DNA-vaccine efficacy in this species.
20. Garver KA, Conway CM, Kurath G: Introduction of translation stop codons into the viral glycoprotein gene in a fish DNA vaccine eliminates induction of protective immunity. Mar Biotechnol (2006) 8(4):351-356.
21. Corbeil S, Kurath G, LaPatra SE: Fish DNA vaccine against infectious hematopoietic necrosis virus: Efficacy of various routes of immunisation. Fish Shellfish Immunol (2000) 10(8):711-723.
22. Dijkstra JM, Fischer U, Sawamoto Y, Ototake M, Nakanishi T: Exogenous antigens and the stimulation of MHC class I restricted cell-mediated cytotoxicity: Possible strategies for fish vaccines. Fish Shellfish Immunol (2001) 11(6):437-458.
23. Pashine A, Valiante N, Ulmer JB: Targeting the innate immune response with improved vaccine adjuvants. Nat Med (2005) 11(4 Suppl):S63-68.
24. Sasaki S, Tsuji T, Hamajima K, Fukushima J, Ishii N, Kaneko T, Xin KQ, Mohri H, Aoki I, Okubo T, Nishioka K, Okuda K: Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect Immun (1997) 65(9):3520-3528.
25. Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB: Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine (2004) 22(13-14):1782-1790.
26. Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N: Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukocyte Biol (2005) 78(3):647-655.
27. Calarota SA, Weiner DB: Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 199:84-99.
28. Tudor D, Dubuquoy C, Gaboriau V, Lefèvre F, Charley B, Riffault S: TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine (2005) 23(10):1258-1264. • The use of TLR9 knockout mice demonstrated that this signaling pathway contributes to DNA vaccine potency, but is not essential.
29. +/+ mice display similar immune responses to a DNA vaccine. Immunology (2004) 113(1):114-120. • The use of TLR9 knockout mice demonstrates that this signaling pathway contributes to DNA vaccine potency, but is not essential.
30. Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB: Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine (2004) 22(13-14):1744-1750.
31. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M et al: Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 175(1):112-123.
32. Bower JF, Green TD, Ross TM: DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology (2004) 328(2):292-300.
33. González-Smith A, Vemulapalli R, Andrews E, Oñate A: Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. Immunobiology (2006) 211(1-2):65-74.
34. Kim SJ, Suh D, Park SE, Park JS, Byun HM, Lee C, Lee SY, Kim I, Oh YK: Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES. Virology (2003) 314(1):84-91.
35. Schirmbeck R, Riedl P, Kupferschmitt M, Wegenka U, Hauser H, Rice J, Kröger A, Reimann J: Priming protective CD8 T cell immunity by DNA vaccines encoding chimeric, stress protein-capturing tumor-associated antigen. J Immunol (2006) 177(3):1534-1542.
36. Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD: Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res (2006) 12(18):5511-5519.
37. Lu M, Isogawa M, Xu Y, Hilken G: Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte- associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol (2005) 79(10):6368-6376.
38. Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, Ishii N et al: Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol (2006) 80(13):6218-6224.
39. Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X et al: DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res (2005) 65(8):3410-3418. • In situ production and immunogenicity of a carbohydrate mimetic by a DNA vaccine provides proof-of-concept that DNA vaccines can be used to elicit immune responses against non-proteinaceous antigens.
40. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM: Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol (2000) 165(5):2850-2858.
41. Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan DT, Donnelly JJ, Ott G, McDonald DM: Mechanisms of increased immunogenicity for DNA-based vaccines absorbed onto cationic microparticles. Cell Immunol (2003) 225(1):12-20.
42. Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH: Poly(DL- lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine (1997) 15(8):814-817.
43. Sharpe S, Hanke T, Tinsley-Bown A, Dennis M, Dowall S, McMichael A, Cranage M: Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology (2003) 313(1):13-21.
44. Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D et al: Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 79(13):8189-8200.
45. Garzón MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, Van Rooijen N, Ruiz J, Prieto J, Zulueta J et al: Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine (2005) 23(11):1384-1392.
46. Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J: Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS (2005) 19(11):1173-1181.
47. Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA: Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine (2004) 22(17-18):2261-2272.
48. Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K et al: Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine (2003) 21(11-12):1103-1111.
49. Caulfield MJ, Wang S, Smith JG, Tobery TW, Liu X, Davies ME, Casimiro DR, Fu TM, Simon A, Evans RK, Emini EA, Shiver J: Sustained peptide-specific γ interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J Virol (2002) 76(19):10038-10043.
50. Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S: Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine (2004) 22(27-28):3603-3612.
51. Roy K, Mao HQ, Huang SK, Leong KW: Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med (1999) 5(4):387-391.
52. Takamura S, Niikura M, Li TC, Takeda N, Kusagawa S, Takebe Y, Miyamura T, Yasutomi Y: DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther (2004) 11(7):628-635.
53. Karpenko LI, Nekrasova NA, Ilyichev AA, Lebedev LR, Ignatyev GM, Agafonov AP, Zaitsev BN, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Bazhan SI: Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine (2004) 22(13-14):1692-1699.
54. HVTN 049 HIV vaccine trial. HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (2004). http://www.hvtn. org/faq/049/hvtn049en.pdf
55. Fuller DH, Murphey-Corb M, Clements J, Barnett S, Haynes JR: Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J Med Primatol (1996) 25(3):236-241.
56. Fuller DH, Loudon P, Schmaljohn C: Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods (2006) 40(1):86-97.
57. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB: Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 164(9):4635-4640.
58. Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, Simon AJ, Laufer R, La Monica N, Cortese R, Nicosia A: Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol (2000) 74(24):11598-11607.
59. Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, Rabussay D, Barnett S, Ulmer JB: Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine (2006) 24(21):4503-4509.
60. Ulmer, JB, Wahren B, Liu MA: Gene-based vaccines: Recent technical and clinical advances. Trends Mol Med (2006) 12(5):216-222.
61. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach V, Roberts J et al: Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol (2006) 80(10):4717- 4728. • One of three papers demonstrating proof-of-concept for the prime-boost approach in clinical trials.
62. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM et al: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 9(6):729-735. • One of three papers demonstrating proof-of-concept for the prime-boost approach in clinical trials.
63. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV: Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis (2004) 189(12):2213- 2219. • One of three papers demonstrating proof-of-concept for the prime-boost approach in clinical trials.
64. Cai H, Yu DH, Hu XD, Li SX, Zhu YX: A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol (2006) 25(8):438-447.
65. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S et al: Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology (2006) 346(1):151-168.
66. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I et al: Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol (2005) 34(5-6):226-236.
67. Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S et al: Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine (2005) 23(19):2454-2464.